Sichenzia Ross Ference Kesner LLP Represents Roth Capital Partners and Brookline Securities in a $5.5 Million Public Offering of QBIO Med.
Press Release – New York, NY – February 1, 2018 – Sichenzia Ross Ference Kesner LLP announced today that it has represented Roth Capital Partners LLC as lead Placement Agent and CIM/Brookline Securities, as Co-Lead Placement Agent in a public offering of Common Stock and Warrants Series for QBIO Med, Inc. (OTC.QBIO). QBIO is a biotechnology acceleration and development company focused on acquiring and in-licensing life science therapeutics products.
QBIO received approximately $5.5 million in gross proceeds from the sale of 1,711,875 shares of Common Stock and Common Stock Purchase Warrants sold to the public at a combined price of $3.20 per share. The five year warrants have an exercise price of $3.20 per share. The Common Stock is traded on OTCQB Market under the symbol “QBIO.” The offering is expected to close on or around February 1, 2018, subject to the satisfaction of customary closing conditions.
The Sichenzia Ross Ference Kesner LLP team was led by partners Gregory Sichenzia and Jay Yamamoto.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Partner Harvey Kesner Publishes Article on US Regulators’ Struggle to Address Cryptocurrenices, ICOs and STOs - June 22, 2018
- Sichenzia Ross Ference Kesner LLP Represents ThinkEquity, a Division of Fordham Financial Management as Sole Book-Running Manager on $18 Million Public Offering of Securities of Trovagene, Inc. - June 12, 2018
- 33/34 Act, M & A Corporate Associate - June 11, 2018